Digestive Diseases and Sciences

, Volume 57, Issue 6, pp 1664–1671

Corticosteroid Plus Pentoxifylline Is Not Better than Corticosteroid Alone for Improving Survival in Severe Alcoholic Hepatitis (COPE Trial)

  • Sandeep Singh Sidhu
  • Omesh Goyal
  • Preeti Singla
  • Dinesh Gupta
  • Ajit Sood
  • Rajoo Singh Chhina
  • Ravinder Kumar Soni
Original Article

Abstract

Background

Corticosteroids and pentoxifylline reduce short-term mortality in severe alcoholic hepatitis (SAH), but not to the extent desired. Combining both drugs may lead to better survival, but has not yet been studied.

Aim

To compare the efficacy of corticosteroids plus pentoxifylline with that of corticosteroids alone in improving survival of SAH patients.

Methods

Of the 111 patients screened, 70 patients with SAH (Maddrey discriminant function (MDF) ≥ 32) were enrolled. Patients with active infection, bleeding, renal failure, or pancreatitis were excluded. Treatment was given for four weeks to group A (n = 36; prednisolone 40 mg/day plus pentoxifylline 400 mg thrice/day) and group B (n = 34; prednisolone 40 mg/day). Patients were followed up for 6 months. Data are expressed as median (range) or percentage.

Results

Baseline characteristics of the two groups were similar (MDF group A 78.5 (36.8–140.9), group B 74.9 (45.6–140.2)). Four-week and six-month survival in groups A and B were not significantly different (four-week 72.2 and 73.5%, respectively, p = 1.00; six-month 30.6 and 23.5%, respectively, p = 0.417). At seven days, 55.6% of patients in group A and 64.7% in group B had a Lille score <0.45 (p = 0.473). Six-month survival was significantly higher for patients with a Lille Score <0.45 than for those with a Lille score ≥0.45 (group A 55.5 vs. 0%, p = 0.0006; group B 36 vs. 0%, p = 0.0304). Biological improvement at 28 days was significant for both groups; however, the difference between the groups was not significant.

Conclusions

For patients with severe alcoholic hepatitis, a combination of corticosteroids and pentoxifylline has no additional survival advantage compared with corticosteroids alone.

Keywords

Corticosteroids Lille score Pentoxifylline Severe alcoholic hepatitis 

References

  1. 1.
    Mathurin P. Corticosteroids for alcoholic hepatitis—what’s next? J Hepatol. 2005;43:526–533.PubMedCrossRefGoogle Scholar
  2. 2.
    Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360:2758–2769.PubMedCrossRefGoogle Scholar
  3. 3.
    Taieb J, Mathurin P, Elbim C, et al. Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. J Hepatol. 2000;32:579–586.PubMedCrossRefGoogle Scholar
  4. 4.
    Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med. 1990;172:391–394.PubMedCrossRefGoogle Scholar
  5. 5.
    Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis: a meta analysis adjusting for confounding variables. Ann Intern Med. 1990;113:299–307.PubMedGoogle Scholar
  6. 6.
    Daures JP, Peray P, Bories P, et al. Corticoid therapy in the treatment of acute alcoholic hepatitis. Results of a meta-analysis. Gastroenterol Clin Biol. 1991;15:223–228.PubMedGoogle Scholar
  7. 7.
    Mathurin P, Mendenhall CL, Carithers RL Jr, et al. Corticosteroids improve short term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol. 2002;36:480–487.PubMedCrossRefGoogle Scholar
  8. 8.
    Mathurin P, O’Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2011;60:255–260.PubMedCrossRefGoogle Scholar
  9. 9.
    Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta analysis adjusting for confounding variables. Gut. 1995;37:113–118.PubMedCrossRefGoogle Scholar
  10. 10.
    Rambaldi A, Saconato HH, Christensen E, et al. Systematic review: glucocorticosteroids for alcoholic hepatitis—a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther. 2008;27:1167–1178.PubMedCrossRefGoogle Scholar
  11. 11.
    Imperiale TF, O’Connor J, McCullough AJ. Corticosteroids are effective in patients with severe alcoholic patients. Am J Gastroenterol. 1999;94:3066–3067.PubMedCrossRefGoogle Scholar
  12. 12.
    Christensen E. Alcoholic hepatitis—glucocorticosteroids or not? J Hepatol. 2002;36:547–548.PubMedCrossRefGoogle Scholar
  13. 13.
    Mathurin P. The use of corticosteroids in severe alcohol hepatitis: we need to look beyond this controversy. J Hepatol. 2010;53:392–393.PubMedCrossRefGoogle Scholar
  14. 14.
    Christensen E. Glucocorticosteroids in acute alcoholic hepatitis: the evidence of a beneficial effect is getting even weaker. J Hepatol. 2010;53:390–391.PubMedCrossRefGoogle Scholar
  15. 15.
    Mc Cullough AJ, O’ Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol. 1998;93:2022–2036.Google Scholar
  16. 16.
    O’Shea RS, McCullough AJ. Treatment of alcoholic hepatitis. Clin Liver Dis. 2005;9:103–134.PubMedCrossRefGoogle Scholar
  17. 17.
    O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Am J Gastroenterol. 2010;105:14–32.PubMedCrossRefGoogle Scholar
  18. 18.
    Sass DA, Shaikh OS. Alcoholic hepatitis. Clin Liver Dis. 2006;10:219–237.PubMedCrossRefGoogle Scholar
  19. 19.
    Doherty GM, Jensen JC, Alexander HR, et al. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery. 1991;110:192–198.PubMedGoogle Scholar
  20. 20.
    Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:1637–1648.PubMedCrossRefGoogle Scholar
  21. 21.
    Sidhu SS, Goyal O, Singla M, et al. Pentoxifylline in severe alcoholic hepatitis: a prospective randomized trial. Trop Gastroenterol. 2009;30:S21–S22.Google Scholar
  22. 22.
    De BK, Gangopadhyay S, Dutta D, et al. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol. 2009;15:1613–1619.PubMedCrossRefGoogle Scholar
  23. 23.
    Louvet A, Diaz E, Dharancy S, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol. 2008;48:465–470.PubMedCrossRefGoogle Scholar
  24. 24.
    Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23:164–176.PubMedCrossRefGoogle Scholar
  25. 25.
    Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011;365:1790–1800.PubMedCrossRefGoogle Scholar
  26. 26.
    Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007;45:1348–1354.PubMedCrossRefGoogle Scholar
  27. 27.
    Mathurin P, Abdelnour M, Ramond MJ, et al. Early change in bilirubin levels (ECBL) is an important prognostic factor in severe biopsy proven alcoholic hepatitis (AH) treated by prednisolone. Hepatology. 2003;38:1363–1369.PubMedGoogle Scholar
  28. 28.
    Mathurin P, Louvet A, Dao T, et al. Addition of pentoxifylline to prednisolone for severe alcoholic hepatitis does not improve 6-month survival: results of the Corpentox trial. Hepatology. 2011;54:81A.Google Scholar
  29. 29.
    Mendenhall C, Roselle GA, Gartside P, et al. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans administration cooperative studies. Alcohol Clin Exp Res. 1995;19:635–641.PubMedCrossRefGoogle Scholar
  30. 30.
    Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005;41:353–358.PubMedCrossRefGoogle Scholar
  31. 31.
    Dureja P, Lucey MR. The place of liver transplantation in the treatment of severe alcoholic hepatitis. J Hepatol. 2010;52:759–764.PubMedCrossRefGoogle Scholar
  32. 32.
    Singal AK, Bashar H, Anand BS, et al. Graft and patient survival after liver transplantation for alcoholic hepatitis—comparison to alcoholic cirrhosis: exploratory analysis based on UNOS data. Hepatology. 2011;54:162A.Google Scholar
  33. 33.
    Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011;365:1781–1789.PubMedCrossRefGoogle Scholar
  34. 34.
    Brown RS Jr. Transplantation for alcoholic hepatitis—time to rethink the 6-month “rule.” N Engl J Med. 2011;365:1836–1838.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Sandeep Singh Sidhu
    • 1
  • Omesh Goyal
    • 1
  • Preeti Singla
    • 2
  • Dinesh Gupta
    • 2
  • Ajit Sood
    • 1
  • Rajoo Singh Chhina
    • 1
  • Ravinder Kumar Soni
    • 3
  1. 1.Department of GastroenterologyDayanand Medical College and HospitalLudhianaIndia
  2. 2.Department of MedicineDayanand Medical College and HospitalLudhianaIndia
  3. 3.Department of Community MedicineDayanand Medical College and HospitalLudhianaIndia

Personalised recommendations